Sale to Industrial
Weifa sold to Aqualis
Weifa AS, a Norwegian pharmaceutical company, announced on 17 June 2014 that the owners of the company have reached an agreement with Aqualis ASA, the Norwegian listed company, for the sale of 100% of the shares in the company for a cash consideration based on an enterprise value of NOK 1,170m.
NOK 1,170m - 2014

Finding a new home for the family business

Weifa’s Consumer Health business holds well-known Norwegian brands such as Paracet, Ibux, Paralgin forte and Pyrisept. Weifa reported revenue of NOK 546m and an adjusted EBITDA of NOK 92m in 2013.

Alpha Corporate Finance has acted as the exclusive financial advisor to Weifa and its shareholders.

Weifa is a leading Norwegian fully-integrated pharmaceutical company, with head office in Oslo and two production plants in Kragerø. Weifa has three business areas: Consumer Health, Metformin APIs and Opioid APIs. Weifa has a highly experienced management team with a proven track record of successful product development and profitable growth Weifa has been a family owned business since established in 1940 by the Weider family. The company was prior to the transaction mainly owned by the Weider family, the Grøner family, the Torbjørnsen family and management.

Aqualis is a Norwegian public company focusing on building a profitable and successful business based on its key competencies within the healthcare and marine and offshore sectors.

Alpha logo